Researchepitalonepithalaminlongevityfda

Review finds no adequately powered randomized trial supports epitalon

Human evidence is limited to small biomarker studies and an older controlled study in retinitis pigmentosa, the authors write.

By Priya Raman · Science Reporter

Oct 7 20:00 ETSource: International journal of molecular sciences

The wire

01A narrative review in the International Journal of Molecular Sciences searched literature through 22 September 2026 and found epitalon biologically active but clinically unproven.
02Readers tracking longevity peptides get a sourced appraisal: pharmacokinetic, dose-ranging and long-term safety data are inadequate, with oncologic and immunogenicity questions open.
03The authors note product-quality and regulatory uncertainty after a 2026 FDA advisory review, and treat epithalamin studies separately as historical context.

From the source

Epitalon and Epithalamin: A Narrative Review of Mechanistic, Preclinical, and Clinical Evidence
International journal of molecular sciences · 2026 Oct 8 · Jain A, Gallacher DM, Issa MA et al.

Read at pubmed.ncbi.nlm.nih.gov

Source URL https://pubmed.ncbi.nlm.nih.gov/42884164/